ENDOTHELIAL-LYMPHOCYTE INTERACTIONS IN THE RETINA

视网膜内皮细胞与淋巴细胞的相互作用

• 批准号: 3264759
• 负责人: REUBEN EISENSTEIN
• 金额: $ 10.86万
• 依托单位: SINAI SAMARITAN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-04-01 至 1994-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3264759
• 关键词: cell cell interaction; cell growth regulation; cellular immunity; eye disorder chemotherapy; growth factor receptors; growth inhibitors; immunosuppression; leukocyte activation /transformation; lymphocyte proliferation; monocyte; retina disorder; retinal pigment epithelium; transforming growth factors; vascular endothelium; vitreous body

The white blood cells which are involved in uveal tract immune-mediated inflammation must adhere to and traverse endothelium to reach the perivascular tissues, where they cause disease. Local factors which modulate lymphocyte responses in eye, including inhibitors of lymphocyte proliferation have been demonstrated in vitreous and in perivascular glial cells. Inhibitors of endothelial cell growth have been demonstrated in vitreous, which are believed to be partly responsible for the normal avascularity of vitreous, one of these appears to be TGF beta. Much work suggests endothelial cells can stimulate lymphocyte proliferation and process antigen. This project aims at analyzing relationships between endothelial cells, lymphocyte function, and the inhibitors previously isolated. It includes a) purification of the lymphocyte inhibitors, and determining if it is the same as the endothelial inhibitor, b) determining at which state of the processes of lymphocyte entry into the tissue, differentiation, and proliferation of lymphocytes the inhibitors works, c) determining whether it is a direct effect on lymphocytes or is mediated through cells which stimulate lymphocytes such as monocytes or endothelial cells, d) determining whether the factor is effective in vivo as well as in tissue culture, e) determining which subpopulations of lymphocytes the factor affects, f) determining whether purified inhibitors of endothelial cell growth have similar effects. The long-term objective is to use these to plan treatments which can suppress the local immune response occurring in immune-mediated ocular disease.

参与葡萄膜免疫介导的白色血细胞 炎症必须粘附并穿过内皮细胞， 血管周围的组织，在那里它们引起疾病。 当地因素， 调节眼部淋巴细胞反应，包括淋巴细胞抑制剂 在玻璃体和血管周围神经胶质细胞中已经证实了增殖 细胞 内皮细胞生长的抑制剂已经在 玻璃体，这被认为是部分负责正常的 玻璃体无血管，其中之一似乎是TGF β。 许多工作 提示内皮细胞可以刺激淋巴细胞增殖， 过程抗原 该项目旨在分析 内皮细胞，淋巴细胞功能，以及以前的抑制剂 与世隔绝 它包括a）淋巴细胞抑制剂的纯化，和 确定其是否与内皮抑制剂相同，B）确定 在淋巴细胞进入组织的过程的哪个状态， 抑制剂起作用，c） 确定它是对淋巴细胞的直接作用还是介导的 通过刺激淋巴细胞如单核细胞或内皮细胞 d）确定所述因子是否在体内以及 组织培养，e）确定哪些淋巴细胞亚群 因子影响，f）确定纯化的内皮抑制剂是否 细胞生长也有类似的效果。 长期目标是利用这些 计划治疗方法来抑制局部免疫反应 免疫介导的眼部疾病。